Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 12/09/24
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisBusiness Wire • 12/08/24
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Business Wire • 12/08/24
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingBusiness Wire • 11/05/24
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024GlobeNewsWire • 10/15/24
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a TurnaroundZacks Investment Research • 10/08/24
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialBusiness Wire • 09/15/24
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaBusiness Wire • 08/19/24